Explore Supplements Subscribe
The VerdictHIGH CONVICTIONVerdict Score 84

CRP is the smoke detector, not the fire — and the supplement aisle is selling you fans.

If you have a "high" hsCRP from a longevity panel, do this before anything else: book a second draw at least two weeks out, away from any acute illness, vaccination, dental work, or vigorous exercise within the prior 72 hours — and treat the average of the two values as your real number.

  1. THE NUMBER THAT CHANGED MY MIND: A 2009 Mendelian randomisation study showed people born with naturally higher CRP genes do not get more heart disease — proving CRP itself is the smoke, not the fire.
  2. THE MYTH THAT WON'T DIE: One CRP value is not a fact about you — official guidance has required two measurements two weeks apart since 2003, and almost no longevity panel does it.
  3. THE ONE CHANGE THAT MATTERS: If yours is genuinely elevated, the highest-leverage single move is losing visceral belly fat — five to ten percent of body weight measurably moves it.

Picture a smoke detector wired into the ceiling. The detector goes off when there's a fire — but the detector itself is not the fire, and disabling the detector doesn't put the fire out. CRP is the detector. The fire is your visceral fat, your smoking, your infection, or your chronic disease — that's what's pumping the smoke.

SH
Dr. Seth Holbrook, DPT — Doctor of Physical Therapy • Coach to 300+ clients
I built The Verdict to cut through recycled health advice and show what the evidence actually supports.

CRP and Inflammation

The smoke detector is not the fire — and the supplement aisle is selling you fans. What actually drives chronic inflammation, and what the evidence says to do about it.

High Conviction
2026-05-02 · Truth Engine · Cardiometabolic

The Practical Takeaway

Practical steps to reduce CRP
  1. Lose visceral body fat first.

    The single biggest lever for chronic CRP elevation in otherwise healthy adults. 5–10% body weight loss measurably moves the marker. Bariatric 10-year data shows hsCRP and total weight loss are tightly linked at year 10.

  2. Stop smoking.

    Graded effect — partial reduction shows benefit, full cessation is the target. Active smokers run measurably higher CRP than former smokers, who run higher than never-smokers.

  3. Adopt a Mediterranean or DASH dietary pattern.

    Modest CRP reductions in elevated-baseline populations over months, not days. Single-fat-source manipulation over five days does not move it.

  4. Train consistently.

    150+ min/week aerobic plus 2× resistance training. Most of the CRP effect is mediated by visceral fat loss, not the exercise itself. Single sessions transiently raise CRP for 24–72 hours — don't measure post-workout.

  5. Treat your actual driver.

    Sleep apnoea, periodontal disease, autoimmune flares, type 2 diabetes, chronic infection. CRP follows the upstream pathology — fix the pathology, the marker follows.

  6. Measure properly.

    Two readings two weeks apart, away from acute illness, vaccination, dental work, or vigorous exercise within 72 hours. Average them. One value tells you almost nothing about chronic risk.

If you have a "high" hsCRP from a longevity panel, do this before anything else: book a second draw at least two weeks out, away from any acute illness, vaccination, dental work, or vigorous exercise within the prior 72 hours, and treat the average of the two values as your real number.

Single-point CRP is the most common clinical error. Official guidance has required two measurements two weeks apart since 2003. Skip the rule and you'll chase a ghost.

Conviction

Verdict — CRP drivers and what works
High Conviction (per-endpoint stratified)

Because the evidence varies sharply by claim — a single overall score would mislead. Each lever sits at a different conviction level depending on the population it was tested in.

Visceral body fat as dominant modifiable driver: HIGH
Mendelian randomisation: CRP itself is not causal for heart disease: HIGH
IL-1β / IL-6 pathway as the causal upstream axis: HIGH
Anti-inflammatory medications in narrow post-MI secondary prevention (CANTOS/COLCOT/LoDoCo2): HIGH
Two-measurements-two-weeks-apart hsCRP rule: HIGH
Smoking as a driver: HIGH
GLP-1 medications anti-inflammatory in type 2 diabetes: MODERATE-HIGH
Chronic exercise → CRP via body fat loss: MODERATE-HIGH
Mediterranean / DASH dietary pattern in elevated-baseline: MODERATE
Periodontal disease contribution: MODERATE
JUPITER hsCRP-statin rule (narrowed by ApoB era): MODERATE
Sleep restriction → CRP (mechanistic plausibility): MODERATE-LOW
Mindfulness in healthy low-baseline adults: LOW (debunked)
Polyphenol / antioxidant supplements in healthy adults: LOW (debunked)
Single-point hsCRP as a stable trait: LOW (debunked)
What would change "CRP is not causal for heart disease"
A high-quality Mendelian randomisation or trial showing that lowering CRP without lowering IL-1β / IL-6 reduces hard cardiovascular events would force re-opening the question. Currently considered closed by Elliott 2009 JAMA and Swerdlow 2012 Lancet.
What would change "anti-inflammatory therapy works only in narrow secondary prevention"
A pre-registered independent primary-prevention trial in adults with hsCRP 2–10 mg/L, low-to-moderate cardiovascular risk, ApoB-controlled, randomised to low-dose anti-IL-6-pathway therapy vs placebo, with hard cardiovascular endpoints over ≥4 years and N ≥5,000, showing event reduction independent of LDL change — would shift hsCRP from "reclassification marker" to "primary treatment target" for that subgroup.

Go Deeper

Want evidence-scored answers to bloodwork questions like this? Join The Verdict — free weekly reviews. Cholesterol, blood pressure, HbA1c, hsCRP — one number at a time, with the evidence ranked so you stop guessing.

Subscribe — free
The Full Picture — Evidence, Debate & Nuance

What Most People Think

The common belief about CRP

That CRP is "the inflammation number" you should chase down with anti-inflammatory supplements, polyphenol stacks, mindfulness apps, and "anti-inflammatory" diets. The wellness pitch: high CRP causes heart attacks, lower CRP equals longevity, and there's a pill, powder, or protocol for it.

That story has two structural problems. CRP itself isn't causal for cardiovascular disease — Mendelian randomisation closed that question in 2009. And in healthy adults with low baseline CRP, almost nothing in the consumer aisle moves the number meaningfully — because there's no inflammatory substrate to suppress.

What the Evidence Actually Shows

Evidence layers behind CRP drivers

CRP is downstream, not the cause of atherosclerosis. StrongHIGH Mendelian randomisation studies of CRP gene variants don't track coronary heart disease risk (Elliott 2009 JAMA, cite-unverified). The actual causal axis is upstream: IL-1β → IL-6 → CRP. The IL-6 receptor MR Consortium 2012 (Lancet, cite-unverified) showed people born with naturally lower IL-6 signalling have lower CRP AND lower CHD risk. CRP is the thermometer reading. The fire is the cytokine pathway.

Visceral body fat is the dominant modifiable driver of chronic low-grade CRP elevation. StrongHIGH SLEEVEPASS 10-year RCT data (Saarinen 2024, N=240): hsCRP nadir at year 3, %TWL ↔ −0.558 with 10-year hsCRP. Mechanism (Kunz 2021, N=39 nondiabetic adults): adipose tissue macrophages activate, release TNF-α and IL-6, the liver makes CRP, systemic inflammation drives muscle mitochondrial impairment and insulin resistance. Lose visceral fat, the marker falls. Don't, it doesn't.

Anti-inflammatory pharmacotherapy upstream of CRP reduces hard CV events — but only in narrow secondary prevention. StrongHIGH (in scope) Three trials independently confirmed it. CANTOS 2017 (canakinumab, IL-1β monoclonal antibody, post-MI hsCRP ≥2: MACE HR 0.85). COLCOT 2019 (colchicine 0.5 mg post-MI: HR 0.77). LoDoCo2 2020 (colchicine in chronic CAD: HR 0.69). All three [cite-unverified]. None of this generalises to healthy adults with no MI history.

GLP-1 receptor agonists are anti-inflammatory in type 2 diabetes beyond glycemic control. StrongMODERATE-HIGH 40-RCT meta-analysis, N=6,029 (Alrasheed 2025, PMID 41625236): CRP SMD −0.59 vs placebo, TNF-α SMD −0.61, IL-6 SMD −0.24. Mechanism plausible (weight loss + direct effect). Whether this extends to non-diabetic weight-management with hard cardiovascular endpoints separable from weight loss alone is the open question.

Mindfulness, polyphenol supplements, and "anti-inflammatory" food patterns barely move CRP in healthy low-baseline adults. Strong (for null direction)LOW (debunked in healthy) Two MBSR RCTs in stressed community adults: null on CRP (Villalba 2019, PMID 31295270). MBSR in young adult cancer survivors: null on CRP/IL-6 (Oswald 2022, PMID 35048316). Vitamin C+E in T1DM adolescents: null (Cazeau 2016). Mixed flavonoid supplement 12 weeks in overweight women: null (Nieman 2017). High-oleic peanuts 12 weeks: null (Barbour 2015). The signal: where there's no inflammatory substrate, there's nothing to suppress. Modest reductions appear only in elevated-baseline subgroups (high BMI, midlife, T2D, MetS, autoimmune).

Smoking is a major modifiable driver, even adjusted for everything else. ModerateHIGH Dominik 2025 (N=339 advanced chronic liver disease cohort, PMID 40899194): active smokers ran higher CRP (0.36 vs 0.21 mg/dL, p=0.035) plus elevated fibrogenic and angiogenic activity markers vs never-smokers. Pattern replicates across general epidemiology — smoking elevates CRP independent of body fat, and former smokers sit between active and never on most inflammatory readouts.

The Debate

Is CRP a useful primary-prevention screening marker?

JUPITER side (2008)

Rosuvastatin 20 mg in adults with LDL <130 + hsCRP ≥2 reduced major cardiovascular events ~44% over 1.9 years. Established hsCRP as a paradigm-shifting primary-prevention statin trigger in low-LDL/high-hsCRP populations [cite-unverified].

vs

Modern guideline drift (2026)

ApoB plus standard risk calculators (PCE, SCORE2, QRISK3) now do most of the work. hsCRP retains a real but smaller role for intermediate-risk reclassification — borderline cases where a high CRP nudges a "treat" decision.

Resolution: JUPITER's rule is real but narrowed. The marker still has clinical utility, just less than 2008 enthusiasm suggested. Don't extrapolate it to "everyone should have hsCRP measured every year."

Does mindfulness lower CRP?

Two recent RCTs (Villalba 2019, Oswald 2022)

Null on CRP in healthy stressed community adults and in young adult cancer survivors. Hypothesised effect did not appear at intent-to-treat group level.

vs

Subgroup signals + foster care RCT

Modest reductions in midlife / high-BMI subgroups (Villalba exploratory). Pace 2013 in foster-care adolescents: practice-volume engagement correlated with lower salivary CRP within the intervention arm (no group difference).

Resolution: population-stratification + dose-as-engagement. Where there's no inflammatory substrate, there's nothing to suppress. Where there is (high BMI, early-life adversity), engagement-volume can move the marker modestly. Healthy adults: the wellness pitch doesn't replicate.

Honest Limitations

Single-measurement instability

Trial / textbook view: hsCRP is a chronic-risk marker with discrete cut-points (<1 low, 1–3 average, >3 high).
Real-world reality: hsCRP is volatile within-individual. A patient at 3.4 mg/L on Tuesday may be at 1.1 mg/L two weeks later. Most longevity panels report a single value as if it were a stable trait.
More conservative

Marker-outcome dissociation

Trial / textbook view: Lowering CRP via any intervention should reduce CV events because CRP tracks risk in epidemiology.
Real-world reality: Lowering CRP via interventions that don't touch IL-1β / IL-6 (antioxidant flooding, mindfulness in healthy adults) produces small biomarker changes with no outcome translation. The 8-supplement Tongue convergence (NAC, NMN, resveratrol, ALA, quercetin, astaxanthin, PQQ, EGCG) is the same pattern in eight different mechanism families.
More conservative

Population extrapolation

Trial / textbook view: If an intervention lowered CRP in a metabolic-disease population, it should help "everyone."
Real-world reality: Almost every meaningful intervention effect on CRP is concentrated in elevated-baseline / metabolically-diseased subgroups. The supplement and wellness industries have generalised disease-population effect sizes to healthy adults whose baseline CRP is already low. There is nothing to lower.
More conservative

The Nuance

The nuance behind CRP interpretation

There IS a real population for whom anti-inflammatory pharmacotherapy works — but it's narrow. Post-MI patients with hsCRP ≥2 mg/L on optimal LDL-lowering therapy have a real cardiovascular event reduction from low-dose colchicine or IL-1β monoclonal antibody (CANTOS / COLCOT / LoDoCo2). That's a cardiologist-managed secondary prevention conversation, not a wellness biohack. Extrapolating colchicine to healthy primary prevention populations is the predictable next mistake — don't help anyone make it.

JUPITER's "treat low-LDL/high-hsCRP with statins" rule was real but narrowed. In 2008 it was paradigm-shifting. In 2026 most of its work is done by ApoB plus standard risk calculators; hsCRP retains a real but smaller role for intermediate-risk reclassification — borderline cases where a high CRP nudges a "treat" decision. It's a complementary marker, not a primary screening target.

Population stratification is the recurring lesson across the cardiometabolic marker quadrad. HbA1c, blood pressure, cholesterol, and now hsCRP all share the same structural pattern: targets are not universal, dominant driver is metabolic substrate, intervention efficacy concentrates in disease subgroups, lifestyle interventions sum sub-additively at the adherence ceiling. If you understand one, you understand the rest.

Acute illness, vaccination, vigorous exercise, dental work, minor injury, menstrual phase — each can transiently elevate hsCRP into the "high" band. Always wait at least 72 hours after vigorous exercise; at least 2 weeks after acute illness or vaccination; require ≥2 measurements ≥2 weeks apart for any chronic-risk interpretation.

Sources

  1. Alrasheed et al. (2025). GLP-1 RA inflammatory biomarker meta-analysis, 40 RCTs N=6,029. CRP SMD −0.59 vs placebo. Front Endocrinol. PMID 41625236.
  2. Saarinen et al. (2024). SLEEVEPASS 10-year hsCRP secondary, RCT N=240. hsCRP nadir at year 3, %TWL ↔ −0.558 with 10-year hsCRP. Obes Surg. PMID 39509008.
  3. Kunz et al. (2021). Adipose tissue macrophages, systemic CRP/TNF-α, insulin resistance. N=39 nondiabetic adults. Am J Physiol Endocrinol Metab. PMID 33998291.
  4. Villalba et al. (2019). Mindfulness × CRP, two RCTs in stressed community adults — null overall, signal in midlife / high-BMI subgroup. PLoS ONE. PMID 31295270.
  5. Oswald et al. (2022). MBSR pilot RCT in young adult cancer survivors. No change in CRP/IL-6; BP improved. Int J Behav Med. PMID 35048316.
  6. Świątkiewicz et al. (2020). Prospective N=204 first STEMI: CRP24 ≥19.67 mg/L → OR 1.47 LVSD at 6 months. Int J Mol Sci. PMID 31991903.
  7. Dominik et al. (2025). N=339 advanced chronic liver disease cohort: active smokers higher CRP (0.36 vs 0.21 mg/dL, p=0.035). Liver Int. PMID 40899194.
  8. Ridker et al. (2017). CANTOS RCT, canakinumab post-MI hsCRP ≥2, N=10,061. MACE HR 0.85, p=0.021, no LDL change. NEJM. [cite-unverified] Industry-funded (Novartis); foundational evidence the IL-1β axis is causal in CV events.
  9. Tardif et al. (2019). COLCOT — colchicine 0.5 mg post-MI, HR 0.77 ischemic CV events. NEJM. [cite-unverified]
  10. Nidorf et al. (2020). LoDoCo2 — colchicine in chronic CAD, HR 0.69 CV death/MI/stroke/revasc. NEJM. [cite-unverified]
  11. Ridker et al. (2008). JUPITER — rosuvastatin in adults with LDL <130 + hsCRP ≥2: relative MACE reduction ~44%. NEJM. [cite-unverified] Established hsCRP as primary-prevention statin trigger in narrow population.
  12. Pearson et al. (2003). AHA/CDC scientific statement — hsCRP cut-points (<1 / 1–3 / >3 mg/L) and "two measurements ≥2 weeks apart" rule. Circulation. [cite-unverified]
  13. Kaptoge et al. (2010). Emerging Risk Factors Collaboration IPMA, 54 cohorts. RR ~1.37 per SD log-CRP for CHD. Lancet. [cite-unverified]
  14. Elliott et al. (2009). Mendelian randomisation — CRP gene variants do NOT track CHD risk. JAMA. [cite-unverified] Falsifies the "CRP itself is causal" framing.
  15. Swerdlow et al. (2012). IL-6R Mendelian Randomisation Consortium — IL-6R Asp358Ala → lower CRP → lower CHD risk per allele. Lancet. [cite-unverified] Establishes IL-6 axis as causal upstream of CRP.

Verdict Score

How strong is the evidence for the claims in this review? Higher = more confidence the claims are supported. This does not measure how large the effect is or how important it is compared with other levers.

84 Strong evidence
80–100Strong evidence ◀
60–79Mixed but supportive
40–59Uncertain
0–39Weak support

Get weekly verdicts — no fluff, just evidence

Conviction-scored health research in your inbox. What works, what doesn't, and what the studies actually measured.

Subscribe free

Related free research

Performance
Body Recomposition — Who Can Actually Do It?
 Performance
Muscle Confusion vs Progressive Overload — The Verdict
 Performance
Travel and Fitness — Maintaining Progress

There are 424 more inside

Conviction-scored verdicts on supplements, nutrition, training, physio, and recovery.

Explore all Get weekly verdicts